Posts Tagged :

Specialty Pharmacy Trends

Shields and Foundation Health Partner to Bring AI to a Rapidly Evolving Specialty Pharmacy Landscape 199 199 Shields Health Solutions

Shields and Foundation Health Partner to Bring AI to a Rapidly Evolving Specialty Pharmacy Landscape

This article was published in Becker’s Hospital Review on March 17, 2026. An article in Becker’s Hospital Review highlights why Shields selected Foundation Health as its partner to build AI‑enabled…

Benchmarking the Future: Industry-Leading Specialty Pharmacy Outcomes 200 200 Shields Health Solutions

Benchmarking the Future: Industry-Leading Specialty Pharmacy Outcomes

Clinical outcomes in specialty pharmacy are more important than ever, yet many leaders still lack clear, comparable benchmarks to guide how they design, measure, and improve their programs.    Leveraging data from the largest health‑system…

2025 Specialty Pharmacy Outcomes Report 70 70 Shields Health Solutions

2025 Specialty Pharmacy Outcomes Report

Specialty pharmacy outcomes, elevated at scale. Download the Full 2025 Specialty Pharmacy Outcomes Report The 5th Annual Shields Specialty Pharmacy Outcomes Report is here. Featuring results from more than 2…

Unlock Your Specialty Pharmacy’s Hidden Value [INFOGRAPHIC] 200 200 Shields Health Solutions

Unlock Your Specialty Pharmacy’s Hidden Value [INFOGRAPHIC]

See how your health system can retain specialty volume, strengthen financial performance, and improve patient outcomes with the right strategy and support. Health systems without fully integrated specialty pharmacy models…

The Hidden Value of Integrated Specialty Pharmacy Partnership 1024 576 Shields Health Solutions

The Hidden Value of Integrated Specialty Pharmacy Partnership

Health systems build business cases for specialty pharmacy around predictable benefits: revenue retention, 340B optimization, and continuity of patient care. But the most significant impacts rarely appear in initial ROI…

Asembia Specialty Pharmacy Summit: Location, Dates, What to Expect, and What’s Happening 70 70 Shields Health Solutions

Asembia Specialty Pharmacy Summit: Location, Dates, What to Expect, and What’s Happening

Every year, more than 8,000 professionals and over 1,400 companies attend the leading specialty pharmacy conference in the nation, Asembia Summit 2025 marked its 21st anniversary — and we couldn’t be…

Revenue and Patient Volume Associated with Accreditation Restricted Limited Distribution Drugs in Health System Specialty Pharmacies 216 115 Shields Health Solutions

Revenue and Patient Volume Associated with Accreditation Restricted Limited Distribution Drugs in Health System Specialty Pharmacies

    Accreditation positions health system specialty pharmacies to expand access to high-value medications and supports integrated caremodels shown to reduce healthcare costs.  

Ambulatory Clinical Pharmacist Impact on Coverage Determinations for Specialty Oncology Medications 216 115 Shields Health Solutions

Ambulatory Clinical Pharmacist Impact on Coverage Determinations for Specialty Oncology Medications

    This poster evaluates the impact of an ambulatory clinical pharmacist (ACP) program on third party pharmacy coverage determinationoutcomes for specialty oncology medications prescribed from these clinics.  

Evaluating Health System Time Demands and Challenges of Specialty Pharmacy Accreditation 216 115 Shields Health Solutions

Evaluating Health System Time Demands and Challenges of Specialty Pharmacy Accreditation

    This poster evaluate the challenges, time commitments, and resource allocation associated withachieving and maintaining SP accreditation among health-system specialty pharmacies.  

Treatment Utilization Patterns and Time To Therapy Discontinuation in Patients with ALK+ Metastatic Non-Small Cell Lung Cancer 216 115 Shields Health Solutions

Treatment Utilization Patterns and Time To Therapy Discontinuation in Patients with ALK+ Metastatic Non-Small Cell Lung Cancer

    This poster explores treatment utilization patterns and time to discontinuation (TTD) in patients receiving ALK TKIs for ALK+ mNSCLC.